Cellworks

Check out our latest blog by Cellworks Chief Scientific Officer, Dr. Ansu Kumar, exploring whether IDH mutations can predict venetoclax response in AML patients. Learn how Cellworks' biosimulation platform uses patient-specific genomics to uncover key molecular pathways and biomarkers that could guide venetoclax treatment decisions for better outcomes. Read more here: https://lnkd.in/gSCFdkJf #AML #Biosimulation #PrecisionMedicine #IDHMutations #Cellworks

A big thanks to Himanshu Grover, Cellworks Lead Scientist R&D, Shweta Kapoor, Cellworks Director of R&D, and Jim Wingrove, Cellworks VP of Clinical Solutions for participating in the ESMO Congress 2024 in Barcelona! Himanshu and Shweta presented new findings on how combining Cellworks biosimulation with tumor Microenvironment (TME) modeling improves predictions of immunotherapy (IO) in NSCLC patients. The research found that utilizing genomic and transcriptomic data with biosimulation goes beyond traditional biomarkers like PD-L1, offering more personalized and effective treatment strategies. You can read the press release about the study at https://shorturl.at/WIgmr. Learn more about how Cellworks is elevating personalized therapy for cancer patients worldwide.  #Biosimulation #PrecisionMedicine #ESMO2024 #Cellworks

At #ESMO24, we unveiled results from a new study showing how PARP inhibitors (PARPi) can benefit patients with ovarian, pancreatic, prostate, and triple-negative breast cancers. Using Cellworks personalized therapy biosimulation, we identified homologous recombination deficiency(HRD) beyond BRCA mutation status, providing more comprehensive predictions of patient response to PARPi therapies. A special thank you to Dr. Daniel Palmer, Principal Investigator of the study, for his work with us and advancing personalized therapy for cancer patients. You can read details about the study here - https://lnkd.in/gDeawZj7 #ESMO24 #PersonalizedMedicine #Biosimulation #Oncology #Cellworks

This week at the IASLC WCLC 2024, Dr. Mark Klein, MD, Staff Physician at the Minneapolis VA Healthcare System, delivered an outstanding oral presentation on our latest NSCLC clinical study. The study showcases how the Cellworks biosimulation platform accurately predicts which NSCLC patients will benefit most from combining chemotherapy with immunotherapy, going beyond PD-L1 status to improve treatment outcomes. A heartfelt thanks to Dr. Klein and Dr. Charu Aggarwal, MD, MPH, Professor of Medicine at the University of Pennsylvania and Penn Center for Cancer Care Innovation, for their exceptional dedication and leadership as Principal Investigators of this important study. This research highlights the transformative potential of personalized therapy decision support in real-world patient cohorts, advancing the future of targeted, effective cancer treatments. You can read the announcement about the study here - https://lnkd.in/gZFCnhuV #Cellworks #WCLC2024 #IASLC #NSCLC #Biosimulation #PersonalizedMedicine #LungCancer

We're pleased to share the latest findings from a Cellworks Personalized Therapy Biosimulation study presented @IASLC 2024 World Conference on Lung Cancer in San Diego. The study predicted chemotherapy benefit in osimertinib-treated NSCLC patients with EGFR mutations by identifying biomarkers linked to their response. A big thank you to Dr. Charu Aggarwal, our Principal Investigator, for her leadership on this study. You can read the announcement about the study here - https://lnkd.in/gvFSTU3T #WCLC24 #LungCancer #Biosimulation #PrecisionMedicine #Cellworks

Discover how a new combination of Ruxolitinib and Sorafenib offers hope for JAK2-mutant Myelofibrosis patients. In a recent blog by Ansu Kumar, Cellworks' Chief Scientific Officer, we explore how our predictive biosimulation approach uncovers synergistic effects that go beyond targeting the JAK2 mutation alone. This innovative strategy could significantly improve treatment outcomes by addressing multiple signaling pathways in myelofibrosis. Dive into the details of this promising research! https://lnkd.in/gephiD7D #CancerResearch #Myelofibrosis #PrecisionMedicine #Biosimulation #Cellworks

We are excited to share a very informative article about Cellworks published by Precision Medicine Online: Cellworks Aims to Validate Clinical Decision Support Capabilities of Computational Model. A special thanks to our collaborators at Avera Cancer Institute, especially Tobias Meissner (Tobias Meißner), Manager of Cancer Genomics, for partnering with us in the myCare-101 study. Together, we are exploring how our personalized therapy biosimulation technology can revolutionize cancer treatment and improve patient outcomes. You can read the full article to learn more about our journey and how we're transforming cancer care! https://lnkd.in/dcnk_kPV #PersonalizedOncology #ComputationalBiology #Biosimulation #CancerResearch #Cellworks #AveraCancerInstitute #PrecisionMedicineOnline

We're excited to announce that Dr. Michael Castro, Chief Medical Officer of Cellworks, will be a distinguished panelist at "The Repurposing Revolution" event on October 15, 2024, in London and online. This event, organized by Yes to Life, is a groundbreaking forum dedicated to exploring Repurposed Drugs for cancer treatment and the latest advancements in this crucial field. Dr. Castro, a renowned medical doctor and neuro-oncologist, will bring his extensive expertise in molecular oncology and personalized medicine to this panel discussion. This event promises to be an invaluable platform for healthcare professionals to delve into the potential of repurposed drugs and engage in insightful discussions with leading experts. Don't miss this opportunity to be part of a revolutionary conversation in cancer treatment!  You can book a ticket here: https://lnkd.in/egaVrwia #PersonalizedMedicine #CancerTreatment #HealthcareInnovation #YesToLife #Cellworks #Oncology 

Are you attending the BIO International Convention in San Diego this week? Connect with our VP of Pharma Solutions, Duane Williams, to discover how Cellworks' Precision Biosimulation solutions can accelerate your drug development goals. We look forward to seeing you there! #BIO2024 #PrecisionDrugDevelopment #Cellworks